Rosuvastatin is known to treat Hyperlipoproteinemia Type III by inhibiting HMG-CoA reductase (HMGCR) and thereby diminishing cholesterol production55,56. This evidence concerns the gene HMGCR and hyperlipoproteinemia type 3.